These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32536268)

  • 1. Impaired wound healing in a migraine patient as a possible side effect of calcitonin gene-related peptide receptor antibody treatment: A case report.
    Wurthmann S; Nägel S; Hadaschik E; Schlott S; Scheffler A; Kleinschnitz C; Holle D
    Cephalalgia; 2020 Oct; 40(11):1255-1260. PubMed ID: 32536268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extreme ecchymoses in a migraine patient using concomitant treatment with calcitonin gene-related peptide receptor antibodies and fish oil supplements: a case report.
    Cullum CK; Olsen MK; Kocadag HB; Ashina M; Amin FM
    BMC Neurol; 2021 Jul; 21(1):257. PubMed ID: 34215196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon.
    Breen ID; Brumfiel CM; Patel MH; Butterfield RJ; VanderPluym JH; Griffing L; Pittelkow MR; Mangold AR
    JAMA Netw Open; 2021 Apr; 4(4):e217934. PubMed ID: 33871613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case reports: Could sexual dysfunction in women with migraine be a side effect of CGRP inhibition?
    Al-Hassany L; Boucherie DM; Couturier EGM; MaassenVanDenBrink A
    Cephalalgia; 2024 May; 44(5):3331024241248837. PubMed ID: 38796855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
    Chiang CC; Schwedt TJ
    Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.
    Scheffler A; Messel O; Wurthmann S; Nsaka M; Kleinschnitz C; Glas M; Naegel S; Holle D
    J Headache Pain; 2020 Jul; 21(1):84. PubMed ID: 32620151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcitonin Gene-Related Peptide (CGRP) Antagonists and Their Use in Migraines.
    Henson B; Hollingsworth H; Nevois E; Herndon C
    J Pain Palliat Care Pharmacother; 2020 Mar; 34(1):22-31. PubMed ID: 31763951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy.
    Mullin K; Kudrow D; Croop R; Lovegren M; Conway CM; Coric V; Lipton RB
    Neurology; 2020 May; 94(20):e2121-e2125. PubMed ID: 31932515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erenumab in the treatment of migraine.
    Jain S; Yuan H; Spare N; Silberstein SD
    Pain Manag; 2018 Nov; 8(6):415-426. PubMed ID: 30235976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review.
    Urits I; Jones MR; Gress K; Charipova K; Fiocchi J; Kaye AD; Viswanath O
    Curr Pain Headache Rep; 2019 Mar; 23(5):29. PubMed ID: 30874961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability evaluation of erenumab for the preventive treatment of migraine.
    Deligianni CI; Mitsikostas DD; Ashina M
    Expert Opin Drug Saf; 2021 Aug; 20(8):867-876. PubMed ID: 34037500
    [No Abstract]   [Full Text] [Related]  

  • 13. Paralytic ileus after planned abdominal surgery in a patient on treatment with erenumab.
    Frattale I; Ornello R; Pistoia F; Caponnetto V; Colangeli E; Sacco S
    Intern Emerg Med; 2021 Jan; 16(1):227-228. PubMed ID: 32557089
    [No Abstract]   [Full Text] [Related]  

  • 14. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.
    Hargreaves R; Olesen J
    Headache; 2019 Jun; 59(6):951-970. PubMed ID: 31020659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis.
    Tringali G; Navarra P
    Peptides; 2019 Jun; 116():16-21. PubMed ID: 31018157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcitonin Gene-Related Peptide Antagonists for the Prevention of Migraine: Highlights From Pivotal Studies and the Clinical Relevance of This New Drug Class.
    Arca K; Reynolds J; Sands KA; Shiue HJ
    Ann Pharmacother; 2020 Aug; 54(8):795-803. PubMed ID: 32019317
    [No Abstract]   [Full Text] [Related]  

  • 17. In brief: Erenumab (Aimovig) hypersensitivity.
    Med Lett Drugs Ther; 2019 Mar; 61(1568):48. PubMed ID: 31022159
    [No Abstract]   [Full Text] [Related]  

  • 18. Ischemic Stroke Associated With Calcitonin Gene-Related Peptide Inhibitor Therapy for Migraine: A Case Report.
    Aradi S; Kaiser E; Cucchiara B
    J Stroke Cerebrovasc Dis; 2019 Oct; 28(10):104286. PubMed ID: 31327684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials.
    Xu D; Chen D; Zhu LN; Tan G; Wang HJ; Zhang Y; Liu L
    Cephalalgia; 2019 Aug; 39(9):1164-1179. PubMed ID: 30789292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erenumab (AMG 334), a monoclonal antagonist antibody against the canonical CGRP receptor, does not impair vasodilatory or contractile responses to other vasoactive agents in human isolated cranial arteries.
    Ohlsson L; Haanes KA; Kronvall E; Xu C; Snellman J; Edvinsson L
    Cephalalgia; 2019 Dec; 39(14):1745-1752. PubMed ID: 31366221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.